| Literature DB >> 31138135 |
Myung-Soo Jang1, Jae-Sik Nam2, Jun-Young Jo2, Chang-Hwa Kang3, Seung Ah Ryu3, Eun-Ho Lee4, In-Cheol Choi2.
Abstract
BACKGROUND: Although serum creatinine concentration has been traditionally used as an index of renal function in clinical practice, it is considered relatively inaccurate, especially in patients with mild renal dysfunction. This study investigated the usefulness of preoperative estimated glomerular filtration rate (eGFR) in predicting complications after cardiovascular surgery in patients with normal serum creatinine concentrations.Entities:
Keywords: Cardiovascular surgery; Glomerular filtration rate, creatinine
Mesh:
Substances:
Year: 2019 PMID: 31138135 PMCID: PMC6540432 DOI: 10.1186/s12871-019-0763-1
Source DB: PubMed Journal: BMC Anesthesiol ISSN: 1471-2253 Impact factor: 2.217
Baseline and intraoperative characteristics of study patients stratified by preoperative eGFR
| eGFR (mL/min/1.73 m2) | ||||||
|---|---|---|---|---|---|---|
| < 60 | 60–74 | 75–89 | 90–104 | ≥ 105 | ||
| N | 185 | 408 | 632 | 717 | 266 | |
| Baseline characteristics | ||||||
| Male gender (n) | 85 (45.9) | 245 (60.0) | 399 (63.1) | 423 (59.0) | 154 (57.9) | 0.001 |
| Age (yr) | 68.8 ± 8.2 | 66.2 ± 9.4 | 63.8 ± 10.6 | 57.7 ± 10.2 | 41.4 ± 11.1 | < 0.001 |
| Body mass index (kg/m2) | 24.1 ± 3.2 | 24.3 ± 3.3 | 24.3 ± 3.2 | 24.2 ± 3.3 | 22.9 ± 3.9 | < 0.001 |
| EuroSCORE (logistic) | 9.6 ± 10.1 | 6.6 ± 6.9 | 6.0 ± 6.7 | 4.6 ± 5.3 | 5.6 ± 7.9 | < 0.001 |
| Hematocrit (%) | 36.3 ± 5.9 | 38.3 ± 5.0 | 39.0 ± 4.9 | 39.1 ± 4.6 | 39.0 ± 5.1 | < 0.001 |
| Creatinine (mg/dL) | 1.2 ± 0.1 | 1.0 ± 0.1 | 0.9 ± 0.1 | 0.8 ± 0.1 | 0.7 ± 0.1 | < 0.001 |
| Bilirubin, total (mg/dL) | 0.7 ± 0.5 | 0.7 ± 0.6 | 0.7 ± 0.4 | 0.6 ± 0.4 | 0.7 ± 0.5 | 0.802 |
| Albumin (g/dL) | 3.6 ± 0.5 | 3.7 ± 0.4 | 3.7 ± 0.5 | 3.7 ± 0.5 | 3.8 ± 0.6 | 0.002 |
| Uric acid (mg/dL) | 7.0 ± 2.0 | 6.2 ± 1.7 | 5.6 ± 1.7 | 5.2 ± 1.5 | 5.0 ± 1.5 | < 0.001 |
| C-reactive protein (mg/dL) | 0.8 ± 2.4 | 0.5 ± 1.3 | 0.6 ± 1.4 | 0.5 ± 1.3 | 1.1 ± 2.7 | 0.209 |
| Left ventricle ejection fraction (%) | 55.2 ± 11.4 | 57.0 ± 10.7 | 58.1 ± 10.5 | 59.3 ± 9.9 | 58.7 ± 10.1 | < 0.001 |
| Diabetes mellitus | 62 (33.5) | 111 (27.2) | 138 (21.8) | 150 (20.9) | 22 (8.3) | < 0.001 |
| Hypertension | 119 (64.3) | 243 (59.6) | 331 (52.4) | 306 (42.7) | 58 (21.8) | < 0.001 |
| Congestive heart failure | 18 (9.7) | 36 (8.8) | 47 (7.4) | 48 (6.7) | 13 (4.9) | 0.225 |
| Cerebrovascular disease | 29 (15.7) | 47 (11.5) | 47 (7.4) | 52 (7.3) | 13 (4.9) | < 0.001 |
| Peripheral vascular disease | 21 (11.4) | 48 (11.8) | 50 (7.9) | 54 (7.5) | 43 (16.2) | < 0.001 |
| Liver disease | 10 (5.4) | 17 (4.2) | 28 (4.4) | 40 (5.6) | 10(3.8) | 0.683 |
| Chronic obstructive pulmonary disease | 8 (4.3) | 21 (5.1) | 28 (4.4) | 24 (3.3) | 9 (3.4) | 0.604 |
| Dyslipidemia | 147 (79.5) | 333 (81.6) | 510 (80.7) | 581 (81.0) | 180 (67.7) | < 0.001 |
| Smoker, current | 19 (10.3) | 60 (14.7) | 86 (13.6) | 149 (20.8) | 67 (25.2) | < 0.001 |
| ACEI or ARB | 120 (64.9) | 219 (53.7) | 283 (44.8) | 305 (42.5) | 93 (35.0) | < 0.001 |
| β-blocker | 97 (52.4) | 208 (51.0) | 295 (46.7) | 278 (38.8) | 96 (36.1) | < 0.001 |
| Calcium channel blocker | 100 (54.1) | 200 (49.0) | 304 (48.1) | 286 (39.9) | 76 (28.6) | < 0.001 |
| Diuretics | 111 (60.0) | 210 (51.5) | 276 (43.7) | 255 (35.6) | 86 (32.3) | < 0.001 |
| Insulin | 25 (13.5) | 33 (8.1) | 47 (7.4) | 50 (7.0) | 12 (4.5) | 0.009 |
| Oral hypoglycemic agent | 48 (25.9) | 92 (22.5) | 117 (18.5) | 116 (16.2) | 18 (6.8) | < 0.001 |
| Aspirin | 84 (45.4) | 194 (47.5) | 280 (44.3) | 271 (37.8) | 58 (21.8) | < 0.001 |
| Clopidogrel | 48 (25.9) | 109 (26.7) | 162 (25.6) | 160 (22.3) | 24 (9.0) | < 0.001 |
| Statins | 107 (57.8) | 241 (59.1) | 326 (51.6) | 347 (48.4) | 69 (25.9) | < 0.001 |
| Intraoperative data | ||||||
| Type of surgery | ||||||
| Coronary artery bypass grafting | 36 (19.5) | 114 (27.9) | 184 (29.1) | 196 (27.3) | 37 (13.9) | < 0.001 |
| Valve | 86 (46.5) | 181 (44.4) | 291 (46.0) | 347 (48.4) | 134 (50.4) | 0.531 |
| Aorta | 12 (6.5) | 23 (5.6) | 28 (4.4) | 37 (5.2) | 32 (12.0) | < 0.001 |
| Combined | 51 (27.6) | 90 (22.1) | 129 (20.4) | 137 (19.1) | 63 (23.7) | 0.102 |
| Off-pump surgery | 25 (13.5) | 85 (20.8) | 146 (23.1) | 149 (20.8) | 31 (11.7) | < 0.001 |
| Operation time (min) | 327.3 ± 110.9 | 311.5 ± 101.4 | 311.4 ± 100.2 | 300.9 ± 94.2 | 316.6 ± 116.7 | 0.065 |
| Cardiopulmonary bypass time (min) | 133.7 ± 84.9 | 114.8 ± 80.0 | 115.7 ± 84.8 | 114.7 ± 81.0 | 136.6 ± 81.0 | 0.575 |
| Total crystalloid (L) | 1.9 ± 0.8 | 2.1 ± 1.1 | 2.0 ± 1.0 | 1.9 ± 0.9 | 1.9 ± 1.0 | 0.058 |
| Total colloid (L) | 0.6 ± 0.3 | 0.6 ± 0.3 | 0.6 ± 0.3 | 0.6 ± 0.3 | 0.5 ± 0.3 | 0.093 |
| Packed red blood cell (unit) | 1.4 ± 2.3 | 1.2 ± 1.8 | 1.2 ± 2.1 | 0.7 ± 1.4 | 1.1 ± 2.4 | < 0.001 |
| Fresh frozen plasma (unit) | 1.3 ± 2.1 | 1.1 ± 2.1 | 1.1 ± 2.2 | 0.8 ± 1.8 | 1.5 ± 3.2 | 0.528 |
| Use of platelet concentrate | 66 (35.7) | 113 (27.7) | 177 (28.0) | 139 (19.4) | 86 (32.3) | < 0.001 |
| Use of cryoprecipitate | 22 (11.9) | 46 (11.3) | 70 (11.1) | 56 (7.8) | 38 (14.3) | 0.034 |
Data are expressed as number of patients (%) or mean ± standard deviation
For comparisons, one-way analysis of variance or Kruskal–Wallis test for continuous variables and the χ2 test for categorical variables were used, as appropriate
eGFR estimated glomerular filtration rate, EuroSCORE European System for Cardiac Operative Risk Evaluation, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
Fig. 1Flow diagram of the study, showing patients included and excluded. sCr = serum creatinine, IABP = intra-aortic balloon pump, VAD = ventricular assist device
Fig. 2Relationship between preoperative eGFR and composite 90 day postoperative major complications as evaluated by (a) descriptive statistics and (b) logistic regression analysis. The 95% confidence intervals are denoted by error bars in a and bands around the regression line in b. eGFR = estimated glomerular filtration rate
Fig. 3Effects of preoperative eGFR on the rates of 90-day (a) mortality, (b) MACCE, (c) pulmonary complications, and (d) renal complications after cardiovascular surgery. eGFR = estimated glomerular filtration rate; MACCE = major adverse cardiovascular and cerebrovascular event
Univariate and multivariable predictors for composite 90-day major complications after cardiovascular surgery
| Predictor | Univariatea | Multivariableb | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| eGFRc | 1.259 (1.176–1.347) | < 0.001 | 1.232 (1.148–1.322) | < 0.001 |
| Age | 1.028 (1.017–1.038) | < 0.001 | ||
| Body mass index (kg/m2) | 0.965 (0.931–1.000) | 0.052 | ||
| EuroSCORE (logistic) | 1.070 (1.054–1.086) | < 0.001 | ||
| Hematocrit (%) | 0.908 (0.887–0.929) | < 0.001 | 0.963 (0.937–0.989) | 0.005 |
| Bilirubin, total (mg/dL) | 1.514 (1.228–1.868) | < 0.001 | 1.368 (1.090–1.717) | 0.007 |
| Serum albumin (g/dL) | 0.278 (0.219–0.352) | < 0.001 | 0.363 (0.276–0.478) | < 0.001 |
| Uric acid (mg/dL) | 1.101 (1.032–1.175) | 0.003 | ||
| C-reactive protein (mg/dL) | 1.249 (1.175–1.327) | < 0.001 | ||
| LVEF (%) | 0.980 (0.970–0.990) | < 0.001 | ||
| Congestive heart failure | 2.077 (1.427–3.023) | < 0.001 | ||
| Peripheral vascular disease | 1.801 (1.295–2.538) | 0.001 | 1.882 (1.295–2.736) | 0.001 |
| Liver disease | 1.753 (1.094–2.809) | 0.020 | ||
| Dyslipidemia | 0.719 (0.547–0.944) | 0.018 | ||
| Smoker, current | 1.622 (1.149–2.290) | 0.001 | 1.561 (1.126–2.165) | 0.008 |
| ACEI or ARB | 1.285 (1.016–1.625) | 0.036 | ||
| Insulin | 1.989 (1.368–2.890) | < 0.001 | ||
| Use of diuretics | 2.084 (1.643–2.643) | < 0.001 | 1.562 (1.198–2.037) | 0.001 |
a all variables were initially entered into a full multivariable regression analysis and were removed individually to assess each variable’s contribution to the model using backward elimination process with a P value cutoff of 0.05
b final model, Hosmer-Lemeshow test; P = 0.738, C statistic = 0.724
c for each 10 mL/min/1.73 m2 decrease
OR Odds Ratio, CI confidence interval, eGFR estimated glomerular filtration rate, EuroSCORE European System for Cardiac Operative Risk Evaluation, LVEF Left ventricle ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
The odds ratios of preoperative eGFR for the various complications
| Unadjusted | Multivariable Adjusted | |||
|---|---|---|---|---|
| Odds Ratio (95% CI)i | Odds Ratio (95% CI)i | |||
| 90-day deatha | 1.355 (1.153–1.592) | < 0.001 | 1.253 (1.072–1.465) | 0.005 |
| 90-day MACCEb | 1.224 (1.106–1.353) | < 0.001 | 1.182 (1.068–1.309) | 0.001 |
| 90-day pulmonary complicationsc | 1.360 (1.240–1.490) | < 0.001 | 1.238 (1.119–1.369) | < 0.001 |
| 90-day renal complicationsd | 1.281 (1.147–1.430) | < 0.001 | 1.194 (1.064–1.339) | 0.002 |
| 30-day composite complicationse | 1.355 (1.153–1.592) | < 0.001 | 1.253 (1.072–1.465) | 0.005 |
| 30-day MACCEf | 1.192 (1.072–1.326) | 0.001 | 1.157 (1.040–1.288) | 0.008 |
| 30-day pulmonary complicationsg | 1.349 (1.229–1.481) | < 0.001 | 1.267 (1.151–1.394) | < 0.001 |
| 30-day renal complicationsh | 1.288 (1.151–1.441) | < 0.001 | 1.208 (1.078–1.353) | 0.001 |
a adjusted by history of dyslipidemia, preoperative serum albumin levels, preoperative EuroSCORE (logistic), and preoperative use of diuretics
b adjusted by history of liver disease, current smoking, preoperative EuroSCORE (logistic), preoperative serum total bilirubin and albumin levels, preoperative ejection fraction, preoperative use of statin, and preoperative use of ACEI or ARB
c adjusted by history of peripheral vascular disease and liver disease, current smoking, preoperative EuroSCORE (logistic), preoperative hematocrit, preoperative serum albumin and uric acid levels, and preoperative use of diuretics
d adjusted by history of hypertension, preoperative EuroSCORE (logistic), preoperative hematocrit, preoperative serum total bilirubin and albumin levels, preoperative ejection fraction, preoperative use of statin, and preoperative use of diuretics
e adjusted by history of peripheral vascular disease and liver disease, current smoking, preoperative EuroSCORE (logistic), preoperative hematocrit, preoperative serum total bilirubin and albumin levels, and preoperative use of diuretics
f adjusted by history of liver disease, current smoking, preoperative EuroSCORE (logistic), preoperative serum total bilirubin and albumin levels, preoperative use of statin, and preoperative use of ACEI or ARB
g adjusted by history of peripheral vascular disease and liver disease, current smoking, preoperative EuroSCORE (logistic), preoperative hematocrit, preoperative serum albumin levels, and preoperative use of diuretics
h adjusted by preoperative EuroSCORE (logistic), preoperative hematocrit, preoperative serum total bilirubin and albumin levels, preoperative ejection fraction, and preoperative use of diuretics
i for each 10 U increase in the scale
eGFR estimated glomerular filtration rate, CI confidence interval, MACCE major adverse cardiovascular and cerebrovascular event, EuroSCORE European System for Cardiac Operative Risk Evaluation, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker